RLYB Stock — Rallybio Corporation: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$15.75

Market cap

$84.8M

Cash

$90.7M

Enterprise value

-$5.9M

Balance sheet

Cash	$90.7M
Debt	$0.0M
Net cash	$90.7M
Enterprise value	-$5.9M
Basic shares	5.4M shares
Fully diluted shares	6.4M shares
Fully diluted market cap	$101.5M
Cash per share	$16.86
Quarterly burn	+$45.9M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

5.3M

Pre-funded warrants

0.4M

Options

0.6M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.1M

FDSO

6.4M

Cap table as of 2026-06-30.

Price history

Loading RLYB daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

RLYB116

Phase 1 · Active Modality: small molecule

Target C5

Indications

Complement-related diseases (Phase 1)

Status note Lead program; once-weekly, small-volume subcutaneously injected inhibitor of C5 for complement-related diseases. Completed two Phase 1 studies and a confirmatory PK/PD study in healthy volunteers in 2025 (data reported Q1 2026).

RLYB212

Phase 2 · Terminated

Indications

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) (Phase 2)

Status note Program for the prevention of FNAIT discontinued in April 2025 after Phase 2 PK results did not achieve target concentrations, including the minimum target concentration required for efficacy.

RLYB331

Preclinical · Active Modality: monoclonal antibody

Target MTP-2

Status note Preclinical monoclonal antibody targeting MTP-2. Worldwide exclusive rights obtained in May 2022. Indication not stated in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	926,352	+905,817	0.70%	2026-08-14
Cormorant Asset Management	0	-400,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

RLYB — Rallybio Corporation ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

RLYB — Rallybio Corporation